RNS
ARRY

Robert N. Shapiro’s Array Biopharma Inc ARRY Stock Holding History

Robert N. Shapiro’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,350
Closed -$21K – 970
2013
Q3 		$21K Buy
+3,350
New +$19.9K ﹤0.01% 783

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Robert N. Shapiro's ARRY Position: Q4 2013 in Review

Robert N. Shapiro sold out of Array Biopharma Inc (ARRY) in Q4 2013, closing a stake of 3,350 shares — an estimated $21K sold.

Robert N. Shapiro first reported a position in ARRY in Q3 2013 and held it in 1 quarter. The position peaked at $21K in Q3 2013. 143 funds tracked by Wall St. Rank hold ARRY as of Q4 2013.

  • Robert N. Shapiro reported no remaining Array Biopharma Inc position as of Q4 2013 after selling out during the quarter.
  • Robert N. Shapiro sold 3,350 Array Biopharma Inc shares in Q4 2013, an estimated $21K.
  • Robert N. Shapiro first reported a position in Array Biopharma Inc in Q3 2013 and held it in 1 quarter.
  • Robert N. Shapiro's Array Biopharma Inc position peaked at $21K in Q3 2013.
  • 143 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2013.

Based on Robert N. Shapiro's 13F filing for Q4 2013, filed 6 Feb 2014.